# AEON Biopharma, Inc.: overview AEON · NYSE · CIK 1837607 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/aeon.md) · [Financials](/companies/aeon/financials.md) · [Filings](/companies/aeon/filings.md) · [Insiders](/companies/aeon/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(11.24)](/filings/0001837607-25-000085.md) | not reported | [2.28](/filings/0001837607-26-000042.md) | [(0.60)](/filings/0001837607-26-000062.md) | [(0.39)](/filings/0001837607-25-000085.md) | not reported | [(0.29)](/filings/0001837607-26-000042.md) | [(0.02)](/filings/0001837607-26-000062.md) | | Free cash flow | $k | not reported | not reported | [(7,913)](/filings/0001837607-26-000042.md) | [(2,091) d](/filings/0001837607-26-000062.md) | [(2,596) d](/filings/0001837607-25-000085.md) | [(4,712) d](/filings/0001837607-26-000019.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(0.38)](/filings/0001837607-24-000059.md) | [72.93](/filings/0001837607-26-000019.md) | [(3.95)](/filings/0001837607-26-000019.md) | | Free cash flow | $m | not reported | [(35.9)](/filings/0001837607-24-000059.md) | not reported | [(17.3)](/filings/0001837607-26-000019.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aeon/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Dauntless Investment Group, LLC](/funds/2044285.md) | 2026-06-30 | $9.0m | 12,490,154 | | Added +9,962,379 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $68.6k | 95,311 | | Added +8,249 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $65.1k | 90,529 | | Unchanged | | [Blue Owl Capital Holdings LP](/funds/1858703.md) | 2026-06-30 | $30.5k | 42,353 | | Unchanged | | [Formidable Asset Management, LLC](/funds/1592613.md) | 2026-06-30 | $19.7k | 20,024 | | Unchanged | | [StoneX Group Inc.](/funds/913760.md) | 2026-06-30 | $14.9k | 18,953 | | New +18,953 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $9.9k | 13,713 | | Reduced −989 | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $8.3k | 11,507 | | Unchanged | | [CITIGROUP INC](/funds/831001.md) | 2026-06-30 | $5.3k | 7,315 | | Added +6,573 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $3.6k | 5,062 | | Added +880 | ## Recent filings [All 356 filings](/companies/aeon/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 16:15 ET | [8-K](/filings/0001837607-26-000071.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001837607-26-000071 | | 2026-09-30 | 08:00 ET | [8-K](/filings/0001837607-26-000064.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001837607-26-000064 | | 2026-08-12 | 16:17 ET | [10-Q](/filings/0001837607-26-000062.md) | Quarterly report, period 2026-06-30 | 0001837607-26-000062 | | 2026-08-12 | 16:15 ET | [8-K](/filings/0001837607-26-000061.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001837607-26-000061 | | 2026-08-03 | 16:15 ET | [8-K](/filings/0001837607-26-000057.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001837607-26-000057 | | 2026-07-23 | 16:01 ET | [8-K](/filings/0001837607-26-000055.md) | 8.01 Other events | 0001837607-26-000055 | | 2026-07-15 | 16:01 ET | [8-K](/filings/0001837607-26-000052.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001837607-26-000052 | | 2026-07-09 | 10:57 ET | [S-1/A](/filings/0001104659-26-082167.md) | Registration statement, amended | 0001104659-26-082167 | | 2026-07-08 | 17:26 ET | [S-1](/filings/0001104659-26-081860.md) | Registration statement | 0001104659-26-081860 | | 2026-06-17 | 16:05 ET | [8-K](/filings/0001837607-26-000046.md) | 5.07 Shareholder vote results | 0001837607-26-000046 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001837607-26-000019.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1837607 - Tickers: AEON - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:43 ET. No prices; not investment advice.